{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-118544","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.483213+00:00","generated_at":"2026-05-15T09:24:04.170779+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xilio announces Q4 net income $10.4M, cash $137.5M, runway through 2027","bullets":["Net income of $10.4M in Q4 2025 vs net loss of $13.1M in Q4 2024; full year net loss narrowed to $35.0M from $58.2M.","Cash and cash equivalents $137.5M at Dec 31, 2025, up from $55.3M end of 2024; cash runway extended through end of 2027.","XTX501 (bispecific PD-1/masked IL-2) on track for IND submission mid-2026 and Phase 1 start H2 2026; initial data expected H2 2027.","Advancing masked T cell engagers: CLDN18.2 program preclinical data at AACR April 2026; PSMA/STEAP1 candidate nomination Q2 2026.","Recent capital raises: $35.8M from Series B warrant exercises (Jan 2026) and $40.0M follow-on offering (Feb 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-118544","json":"https://secwatch.observer/filing/0001193125-26-118544.json","markdown":"https://secwatch.observer/filing/0001193125-26-118544.md","text":"https://secwatch.observer/filing/0001193125-26-118544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526118544/0001193125-26-118544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526118544/xlo-20260323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:24:04.170779+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}